SCHEMBL845452

SCHEMBL845452

C[C@@](O)(C(=O)N1CCC[C@H]1C(=O)Nc1ccc(/C=C/c2ccc(NC(=O)[C@@H]3CCCN3C(=O)[C@@](C)(O)c3ccccc3)cc2)cc1)c1ccccc1

nearest known ligand 0.52

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
F2 P00734 2/20 0.52
CYP2C19 P33261 2/20 0.51
CYP2C9 P11712 1/20 0.51
EP300 Q09472 2/20 0.50
CREBBP Q92793 2/20 0.50
ALDH1A1 P00352 3/20 0.49
MAPK1 P28482 2/20 0.49
HTT P42858 2/20 0.49
NPC1 O15118 1/20 0.47
PABPC1 P11940 1/20 0.47
KCNH2 Q12809 1/20 0.46
NPSR1 Q6W5P4 2/20 0.45
LMNA P02545 3/20 0.45
KDM4E B2RXH2 1/20 0.45
POLB P06746 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14723789 0.90 KCNH2 (0.55) F2CYP2C19CYP2C9EP300CREBBP
SCHEMBL3045320 0.87 F2 (0.52) F2CYP2C19CYP2C9EP300CREBBP
SCHEMBL3042978 0.87 F2 (0.52) F2CYP2C19CYP2C9EP300CREBBP
SCHEMBL18887550 0.87 F2 (0.52) F2CYP2C19CYP2C9EP300CREBBP
SCHEMBL13571817 0.85 F2 (0.50) F2CYP2C19CYP2C9EP300CREBBP
SCHEMBL2176369 0.85 F2 (0.50) F2CYP2C19CYP2C9EP300CREBBP
SCHEMBL2176361 0.85 F2 (0.50) F2CYP2C19CYP2C9EP300CREBBP
SCHEMBL14647983 0.85 F2 (0.50) F2CYP2C19CYP2C9EP300CREBBP
SCHEMBL12491697 0.85 F2 (0.50) F2CYP2C19CYP2C9EP300CREBBP
SCHEMBL844919 0.85 NPC1 (0.54) CYP2C19CYP2C9EP300CREBBPALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8143288-B2 Inhibitors of HCV replication BRISTOL-MYERS SQUIBB COMPANY (US) 2012-03-27 US disclosed
US-8143288-B2 Inhibitors of HCV replication BRISTOL-MYERS SQUIBB COMPANY (US) 2012-03-27 US disclosed
EP-1893573-B1 INHIBITORS OF HCV REPLICATION BRISTOL MYERS SQUIBB CO (US) 2010-07-21 EP disclosed